ES2059965T3 - Un procedimiento para preparar una composicion farmaceutica para el tratamiento de enfermedades inflamatorias. - Google Patents

Un procedimiento para preparar una composicion farmaceutica para el tratamiento de enfermedades inflamatorias.

Info

Publication number
ES2059965T3
ES2059965T3 ES90123628T ES90123628T ES2059965T3 ES 2059965 T3 ES2059965 T3 ES 2059965T3 ES 90123628 T ES90123628 T ES 90123628T ES 90123628 T ES90123628 T ES 90123628T ES 2059965 T3 ES2059965 T3 ES 2059965T3
Authority
ES
Spain
Prior art keywords
inflammatory diseases
treatment
pharmaceutical composition
preparing
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90123628T
Other languages
English (en)
Inventor
Kenichi Iwamitsu
Yukio Nakamura
Masahiro Kawasaki
Yoshio Fukui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissho Corp
Original Assignee
Nissho Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18278891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2059965(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nissho Corp filed Critical Nissho Corp
Application granted granted Critical
Publication of ES2059965T3 publication Critical patent/ES2059965T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA PARA TRATAR ENFERMEDADES INFLAMATORIAS, COMPRENDE (A) UNA CANTIDAD EFECTIVA DE ACIDO HIALURONICO O SUS SALES, Y (B) UNA CANTIDAD EFECTIVA DE UN AGENTE ANTI-INFLAMATORIO. LA COMPOSICION PRODUCE UN EFECTO TERAPEUTICO SINERGISTICO EN INFLAMACIONES Y ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS, EN PARTICULAR DE ENFERMEDADES DE ARTICULACION CON INFLAMACION.
ES90123628T 1989-12-21 1990-12-08 Un procedimiento para preparar una composicion farmaceutica para el tratamiento de enfermedades inflamatorias. Expired - Lifetime ES2059965T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33457189 1989-12-21

Publications (1)

Publication Number Publication Date
ES2059965T3 true ES2059965T3 (es) 1994-11-16

Family

ID=18278891

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90123628T Expired - Lifetime ES2059965T3 (es) 1989-12-21 1990-12-08 Un procedimiento para preparar una composicion farmaceutica para el tratamiento de enfermedades inflamatorias.

Country Status (7)

Country Link
US (1) US5095037B1 (es)
EP (1) EP0433817B1 (es)
CA (1) CA2031880C (es)
DE (1) DE69003229T2 (es)
ES (1) ES2059965T3 (es)
FI (1) FI906249L (es)
NO (1) NO177525C (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5990096A (en) * 1990-09-18 1999-11-23 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
JPH06509099A (ja) * 1991-07-03 1994-10-13 サノ・コーポレーシヨン ジクロフエナツクの経皮デリバリーに対する組成物及び方法
US5817642A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Clearing of atherosclerosis
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
CA2122551A1 (en) * 1994-04-29 1995-10-30 Rudolf Edgar Falk Clearing of atherosclerosis
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US6218373B1 (en) 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6147059A (en) * 1992-02-20 2000-11-14 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
US5767106A (en) * 1992-02-21 1998-06-16 Hyal Pharmaceutical Corporation Treatment of disease and conditions associated with macrophage infiltration
US5847002A (en) * 1993-04-16 1998-12-08 Hyal Pharmaceutical Corporation Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
CA2094203A1 (en) * 1993-04-16 1994-10-17 Derek A. Willoughby Inhibition of angiogenesis
GB9425487D0 (en) 1994-12-16 1995-02-15 Res Inst Osteoarthritis treatment
US5939047A (en) * 1996-04-16 1999-08-17 Jernberg; Gary R. Local delivery of chemotherapeutic agents for treatment of periodontal disease
US20030008396A1 (en) * 1999-03-17 2003-01-09 Ku David N. Poly(vinyl alcohol) hydrogel
RU2141828C1 (ru) * 1998-03-26 1999-11-27 ООО "Научно-исследовательский институт атеросклероза" (Медотель) Средство, пролонгирующее эффективность чесночного порошка
EP1140198B1 (en) 1999-01-13 2007-10-31 Alchemia Oncology Pty Limited Use of hyaluronan for the manufacture of a medicament for the enhancement of the efficacy of cytotoxic drugs
US6645485B2 (en) * 2000-05-10 2003-11-11 Allan R. Dunn Method of treating inflammation in the joints of a body
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US6726898B2 (en) 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US6576226B1 (en) 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
WO2002051442A1 (en) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Concomitant drugs
JP4234439B2 (ja) * 2001-03-15 2009-03-04 生化学工業株式会社 Ｉｌ−１２発現調節剤
JP2004535434A (ja) * 2001-06-25 2004-11-25 デピユイ 関節炎にかかった関節の処置のためのグリコサミノグリカン類のリポソームカプセル化
CA2450073C (en) 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
MXPA04001828A (es) * 2001-08-27 2005-03-07 Meditech Res Ltd Protocolos terapeuticos mejorados.
CN1549711A (zh) * 2001-08-30 2004-11-24 ��Ĭ���� 稠合的吡咯化合物在治疗关节软骨或软骨下骨组织退化中的用途
JP2005530768A (ja) * 2002-05-09 2005-10-13 メディジーンズ 血漿または血清を含有した創傷治療用医薬組成物
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
AU2005205422B2 (en) * 2004-01-20 2008-04-24 Panacea Biotec Ltd. Compostions comprising glycosaminoglycan and nonsteroidal anti-inflammatory drug
WO2005077013A2 (en) 2004-02-06 2005-08-25 Georgia Tech Research Corporation Surface directed cellular attachment
EP1729678A4 (en) * 2004-02-06 2011-08-10 Georgia Tech Res Inst LOAD-WEARING BIO-COMPATIBLE DEVICE
US7956180B2 (en) * 2004-05-27 2011-06-07 Novozymes A/S Dried and agglomerated hyaluronic acid product
JP5313497B2 (ja) * 2004-05-27 2013-10-09 ノボザイムス バイオファーマ デーコー アクティーゼルスカブ 乾燥および凝集されたヒアルロン酸生成物
US20050278025A1 (en) * 2004-06-10 2005-12-15 Salumedica Llc Meniscus prosthesis
WO2006039704A2 (en) * 2004-09-30 2006-04-13 Janssen Pharmaceutica, N.V. Pharmaceutical composition and method for treating a joint capsule arthropathy
EP2671508B1 (en) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-informatics system
CA2616607C (en) 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US7323184B2 (en) * 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
EP1922077A4 (en) * 2005-09-07 2013-03-06 Alchemia Oncology Pty Ltd THERAPEUTIC COMPOSITIONS WITH HYALURON AND THERAPEUTIC ANTIBODIES AND TREATMENT PROCEDURES
US8598144B1 (en) 2005-11-10 2013-12-03 Reyn Pharma, Llc Method of administering hyaluronan formulation for the amelioration of osteoarthritis
US9492381B1 (en) 2005-11-10 2016-11-15 Reyn Pharma, Llc Method of administering hyaluronan formulation for preventing and ameliorating osteoarthritis
CA2662581C (en) * 2006-09-13 2018-01-30 Enhance Skin Products, Inc. Cosmetic composition for the treatment of skin and methods thereof
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
FR2918276B1 (fr) * 2007-07-02 2010-01-22 Anteis Sa "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"
FR2918476B1 (fr) * 2007-07-02 2012-08-03 Experts Enlargement Quality Exeq Controle de conformite de donnees.
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
US8178511B1 (en) * 2008-07-02 2012-05-15 Smith James D Method of administering hyaluronan formulation for the amelioration of osteopenia
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
KR20180114970A (ko) 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
FR2945949B1 (fr) * 2009-05-26 2011-05-13 Anteis Sa Hydrogel injectable permettant une supplementation en glycerol dans la peau sur le long terme.
IL206739A (en) 2010-06-30 2016-06-30 David Segal An injectable drug containing silitol as an active substance
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
TWI382841B (zh) * 2010-10-29 2013-01-21 Univ China Medical 用於抑制發炎之醫藥組合物
CA3048443C (en) 2011-05-26 2021-01-05 Cartiva, Inc. Tapered joint implant and related tools
HUE037474T2 (hu) * 2011-07-07 2018-08-28 Holy Stone Healthcare Co Ltd Készítmény gyulladással kapcsolatban rendellenesség kezelésében és megelõzésében történõ alkalmazásra
EP3277219B1 (en) 2015-03-31 2020-07-29 Cartiva, Inc. Hydrogel implants with porous materials
EP3892241A1 (en) 2015-03-31 2021-10-13 Cartiva, Inc. Drill bit for carpometacarpal implant
CA2981074C (en) 2015-04-14 2023-03-28 Cartiva, Inc. Tooling for creating tapered opening in tissue and related methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808576A (en) * 1986-04-28 1989-02-28 Mobay Corporation Remote administration of hyaluronic acid to mammals
ATE129254T1 (de) * 1987-03-19 1995-11-15 Arthropharm Pty Ltd Antientzündungsmittel und zusammensetzungen.

Also Published As

Publication number Publication date
US5095037B1 (en) 1995-12-19
EP0433817B1 (en) 1993-09-08
NO177525B (no) 1995-06-26
US5095037A (en) 1992-03-10
FI906249A0 (fi) 1990-12-18
NO905514D0 (no) 1990-12-20
NO177525C (no) 2000-09-07
FI906249A7 (fi) 1991-06-22
CA2031880A1 (en) 1991-06-22
CA2031880C (en) 1999-09-21
NO905514L (no) 1991-06-24
DE69003229D1 (de) 1993-10-14
FI906249L (fi) 1991-06-22
EP0433817A1 (en) 1991-06-26
DE69003229T2 (de) 1994-04-14

Similar Documents

Publication Publication Date Title
CA2031880A1 (en) Combined anti-inflammatory agent
BR9406979A (pt) Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal
DE69739656D1 (de) 1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabe
ES2080837T3 (es) Tratamiento de estados y enfermedades.
ES2164097T3 (es) Uso de anestesicos topicos para la fabricacion de un medicamento para el tratamiento del asma bronquial.
PT1086702E (pt) Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
MX9703694A (es) Tratamiento profilactico y terapeutico de la sensibilizacion e irritacion de la piel.
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
DE59108854D1 (de) Arzneimittel sowie deren herstellung und deren verwendung bei der bekämpfung von schmerzen und/oder entzündungen an tieren und menschen
GEP20022656B (en) 2-(Purin-9-YL)-Tetrahydrofuran-3,4-Diol Derivatives
UA41989C2 (uk) Фармацевтична композиція у вигляді гелю для лікування захворювань шкіри та спосіб лікування інфікованої шкіри
ES2144119T3 (es) Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada.
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ATE39323T1 (de) Injizierbare loesung zur behandlung von entzuendungen.
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
PT99597B (pt) Processo para a preparacao de derivados do acido hidroxamico que inibem a lipoxigenase
ATE111735T1 (de) Verwendung des wirkstoffs azelastin und glycerinethern zur bekämpfung von psoriasis- erkrankungen.
ES2061989T3 (es) Uso de esteres alquilicos del acido piroglutamico para la fabricacion de un medicamento para el tratamiento de la ictiosis.
ES2090317T3 (es) Uso del acido 3-guanidinopropionico en la fabricacion de un medicamento para el tratamiento y prevencion del exceso de adiposidad.
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
MX9400630A (es) 6-cloro-5-fluoro-3-(2-tenoil)-2-oxindol-1-carboxamida como un agente analgesico y antiinflamatorio.
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
ES2091031T3 (es) Uso de acido hialuronico para prevenir la reestenosis arterial.
AR010432A1 (es) Composiciones farmaceuticas que contienen acido ricinoleico y su uso para la terapia antiinflamatoria y analgesica
MX9306005A (es) Combinaciones de ibupropeno-cafeina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 433817

Country of ref document: ES